Stocktoria
Barinthus Biotherapeutics plc. BRNS
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2021-04-30
Barinthus Biotherapeutics plc. statistics & valuation
Market cap$29.4M
P / B0.4×
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | — | -454.1% | -10463.1% | -9.0% | -16873.5% |
| Net margin | — | -408.0% | -9145.5% | 11.9% | -18979.5% |
| FCF margin | — | -199.3% | -7024.7% | -46.0% | -12585.4% |
| Return on assets | -67.7% | -38.1% | -34.2% | 2.0% | -18.1% |
| Return on equity | -89.4% | -46.9% | -39.2% | 2.2% | -20.1% |
| Current ratio | 7.77 | 8.03 | 12.45 | 17.40 | 20.32 |
| Revenue growth | -100.0% | 1766.5% | -98.2% | 16580.2% | -94.4% |
Source: SEC EDGAR filings · CIK 0001828185 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.